METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PROSTATE CANCER BASED ON LONG NONCODING RNA OVERLAPPING THE LCK GENE THAT REGULATES PROSTATE CANCER CELL GROWTH

Smart overview of the Invention

A novel long noncoding RNA (IncRNA) called HULLK, located within the LCK gene, has been identified as a potential oncogene in prostate cancer (PCa). HULLK is situated in exon six and the 3′UTR of the LCK gene and is believed to play a significant role in regulating the growth of prostate cancer cells. The discovery of this IncRNA opens new avenues for both diagnosing and treating PCa.

Significance of HULLK in Prostate Cancer

Prostate cancer remains a leading cause of cancer-related deaths among men, with many patients eventually developing castration-resistant prostate cancer (CRPC). Despite advancements in treatment, there is an urgent need for more effective therapies. The presence of IncRNAs, like HULLK, which are abundant in various stages of PCa progression, suggests that they could serve as crucial therapeutic targets.

Methods for Modulating HULLK Expression

Several methods are proposed for modulating LCK gene activity through HULLK. This includes administering RNA interference (RNAi) molecules, such as short hairpin RNA (shRNA), designed to target the LCK gene specifically. These RNAi molecules can potentially reduce the expression of HULLK, thereby influencing PCa cell growth and proliferation.

Diagnostic Applications

HULLK can also be utilized as a biomarker for diagnosing prostate cancer. By analyzing samples from patients for the presence and expression levels of HULLK, clinicians may diagnose PCa more accurately. Notably, detecting cytoplasmic HULLK can indicate metastatic disease, enhancing its utility as a diagnostic tool.

Future Implications

The exploration of HULLK's role in PCa signals a promising direction for future research and therapeutic development. By focusing on this IncRNA and its mechanisms, new strategies can emerge to combat advanced prostate cancer effectively. These findings may lead to improved outcomes for patients through targeted therapies and enhanced diagnostic capabilities.